Tirzepatide vs Survodutide
Two dual-agonist strategies compared.
| Attribute | Tirzepatide Dual GIP/GLP-1 receptor agonist | Survodutide GLP-1/Glucagon dual agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Dual-agonist weight loss research | Dual-agonist metabolic research |
| In plain English | Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies. | Like tirzepatide, but the second receptor it targets is glucagon — which boosts energy expenditure and fat oxidation. |
| How it works | Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying. | Activates GLP-1 (appetite, insulin) and glucagon (energy expenditure, fat oxidation) receptors. |
| Researchers study | Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes. | Obesity, NASH/MASH, and metabolic syndrome. |
| Internet discussion | Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules. | Discussed alongside retatrutide as next-gen weight loss research. |
Tirzepatide
Dual-agonist weight loss research
Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies.
Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying.
Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes.
Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules.
Tirzepatide is a dual GLP-1/GIP agonist with strong clinical data for weight reduction and glycemic control.
Survodutide
Dual-agonist metabolic research
Like tirzepatide, but the second receptor it targets is glucagon — which boosts energy expenditure and fat oxidation.
Activates GLP-1 (appetite, insulin) and glucagon (energy expenditure, fat oxidation) receptors.
Obesity, NASH/MASH, and metabolic syndrome.
Discussed alongside retatrutide as next-gen weight loss research.
Survodutide is a dual GLP-1/Glucagon agonist researched for weight and liver outcomes.